enfortumab vedotin

BALLERUP, Denmark, July 9, 2026 LEO Pharma A/S has announced positive results from the Phase 2 TRAPEDS-1 clinical trial...

SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...

KIRKLAND, Quebec, Canada, June 29, 2026 Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) in...

RAHWAY, New Jersey, May 24, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...

Foster City, California, USA – May 22, 2026 Gilead Sciences, Inc. announced the successful completion of its acquisition of...

Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...

RAHWAY, N.J., Dec. 17, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 (EV-304)...

Rahway, N.J., Nov. 21, 2025 — In a major advancement for oncology treatment, the U.S. Food and Drug Administration...